Literature DB >> 11283670

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.

M S Kim1, H J Kwon, Y M Lee, J H Baek, J E Jang, S W Lee, E J Moon, H S Kim, S K Lee, H Y Chung, C W Kim, K W Kim.   

Abstract

Low oxygen tension influences tumor progression by enhancing angiogenesis; and histone deacetylases (HDAC) are implicated in alteration of chromatin assembly and tumorigenesis. Here we show induction of HDAC under hypoxia and elucidate a role for HDAC in the regulation of hypoxia-induced angiogenesis. Overexpressed wild-type HDAC1 downregulated expression of p53 and von Hippel-Lindau tumor suppressor genes and stimulated angiogenesis of human endothelial cells. A specific HDAC inhibitor, trichostatin A (TSA), upregulated p53 and von Hippel-Lindau expression and downregulated hypoxia-inducible factor-1alpha and vascular endothelial growth factor. TSA also blocked angiogenesis in vitro and in vivo. TSA specifically inhibited hypoxia-induced angiogenesis in the Lewis lung carcinoma model. These results indicate that hypoxia enhances HDAC function and that HDAC is closely involved in angiogenesis through suppression of hypoxia-responsive tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283670     DOI: 10.1038/86507

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  211 in total

1.  AngioDB: database of angiogenesis and angiogenesis-related molecules.

Authors:  Tae-Kwon Sohn; Eun-Joung Moon; Seok-Ki Lee; Hwan-Gue Cho; Kyu-Won Kim
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

Review 2.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

Review 3.  Hdac-mediated control of endochondral and intramembranous ossification.

Authors:  Elizabeth W Bradley; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

4.  RNA-seq analysis of the functional compartments within the rat placentation site.

Authors:  Kartik Shankar; Ying Zhong; Ping Kang; Michael L Blackburn; Michael J Soares; Thomas M Badger; Horacio Gomez-Acevedo
Journal:  Endocrinology       Date:  2012-02-21       Impact factor: 4.736

5.  Epigenetics in anoxia tolerance: a role for histone deacetylases.

Authors:  Anastasia Krivoruchko; Kenneth B Storey
Journal:  Mol Cell Biochem       Date:  2010-05-01       Impact factor: 3.396

6.  Compound 9a, a novel synthetic histone deacetylase inhibitor, protects against septic injury in mice by suppressing MAPK signalling.

Authors:  So-Jin Kim; Ki Seon Baek; Hyun-Ju Park; Young Hoon Jung; Sun-Mee Lee
Journal:  Br J Pharmacol       Date:  2016-02-22       Impact factor: 8.739

7.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity.

Authors:  P C Mahon; K Hirota; G L Semenza
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

9.  Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin.

Authors:  Sarah K Harten; Deepa Shukla; Ravi Barod; Alexander Hergovich; Maria S Balda; Karl Matter; Miguel A Esteban; Patrick H Maxwell
Journal:  Mol Biol Cell       Date:  2008-12-10       Impact factor: 4.138

10.  Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Authors:  Jennifer J Wheler; Filip Janku; Gerald S Falchook; Tiffiny L Jackson; Siqing Fu; Aung Naing; Apostalia M Tsimberidou; Stacy L Moulder; David S Hong; Hui Yang; Sarina A Piha-Paul; Johnique T Atkins; Guillermo Garcia-Manero; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2014-01-17       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.